🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchClinicalTrials.gov GLP-1 trial tracker — updated weekly Page 11

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 411 replies 11,865 viewsPage 11 of 20
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
Nov 29, 2024 at 5:04 AM#51
EndoResFellow said:
It helps to ask what evidence would change your mind before you look at any.

Adding a me-too, because a thread of one person's experience is not much use.

21 19emma_london, tammy_FL, Dr.LipidDallas and 18 others
Reply Quote Save Share Report
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Dec 7, 2024 at 12:05 PM#52
EndoResFellow said:
It helps to ask what evidence would change your mind before you look at any.

Coming at EndoResFellow’s question from a different direction. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

22 20Dr.Martinez, mike_mod, SarahChen_PharmD and 19 others
Reply Quote Save Share Report
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Dec 15, 2024 at 7:01 PM#53

The figures, for anyone assembling their own picture. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

23 21patPC_UT, Dr.DermMIA, fiona_VT and 20 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Dec 24, 2024 at 1:53 AM#54

Following on from EndoResFellow — and this may be the naive question:

How would you tell the difference between that and the alternative explanation?

24 22TinaHashiRN, robert_kc, dan_philly and 21 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Jan 1, 2025 at 8:40 AM#55
DanielChem_CHI said:
Say what you would expect to see if you were wrong, before you look.

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

25 23wanda_boise, NurseAsh_DET, BenResearch_OR and 22 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register